{
  "docId": "019de514-f120-743f-9d00-70915b7d1fa5",
  "docSlug": "a9055659e75fd1b92a3c529616eb6953",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 49 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 49,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-f120-743f-9d00-70915b7d1fa5/8",
  "deckHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5",
  "deckJsonHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5.json",
  "deckAnchorHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.189,
        "w": 0.189,
        "x": 0.079,
        "y": 0.546
      },
      "kind": "chart",
      "text": "Ophthalmic Pharmaceuticals 18%, Surgical 19%, Vision Care 63%",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef673226-6678-42eb-ac09-10c7c4a3dfd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.09,
        "x": 0.86,
        "y": 0.31
      },
      "kind": "image",
      "text": "Sanoculis",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "236b2a50-f4ce-4699-81ab-90b5bfcd60c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.01,
        "w": 0.11,
        "x": 0.04,
        "y": 0.94
      },
      "kind": "image",
      "text": "BAUSCH+LOMB",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a168362-cdc0-42ab-805d-590d47e1eeb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.07,
        "x": 0.779,
        "y": 0.31
      },
      "kind": "image",
      "text": "AcuFocus",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea4a500b-8a9f-46b3-b242-e7c6559d3068",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.59,
        "w": 0.207,
        "x": 0.541,
        "y": 0.18
      },
      "kind": "list",
      "text": "Investing in Categories Growing Faster Than Market\n~50% U.S. weekly market share for Lumify® in Redness Reliever Category4; Strong early launch in Canada and acquired rights in 18 additional countries\n46% reported revenue growth for SiHy dailies vs. FY21 Multi-focal and toric launch expected in 2023-2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1db0e833-f1cd-4638-8b60-8a9164e0233b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.249,
        "w": 0.207,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "list",
      "text": "Bausch + Lomb (4Q22 vs. 4Q21 and FY22 vs. FY21)\n0% 4Q22 & FY22 Reported Revenue\n5% 4Q22 & FY22 Organic Revenue 1,2\n5% 4Q22 & FY22 Constant Currency¹",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8496355c-eb68-4fc9-8104-a1ab10426029",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.59,
        "w": 0.207,
        "x": 0.762,
        "y": 0.18
      },
      "kind": "list",
      "text": "Expanding Into New Product Categories\nAcuFocus - IC-8® Apthera ™™ IOL5 Sanoculis - MIMS®6\n2 out of 6 acquisitions/licensing transactions since IPO to enhance pipeline\n6 new product launches including Xipere® and Revive™™ along with geo-expansion for Lumify® and Vyzulta®",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94eabd58-8221-4f7e-b3c3-22c76c41921e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.59,
        "w": 0.207,
        "x": 0.32,
        "y": 0.18
      },
      "kind": "list",
      "text": "Continued Momentum in Key Portfolios\n+10% reported revenue growth in Ocuvite® + PreserVision® vs. FY21; Grew market share in U.S. by 170bps and 120bps, respectively, vs. FY213\n+10% reported revenue growth in Biotrue® Solutions Franchise vs. FY21 Grew market share by 360bps vs. FY213",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d716204c-8d5e-4801-b205-0d7379feb194",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.679,
        "x": 0.29,
        "y": 0.834
      },
      "kind": "paragraph",
      "text": "Seventh consecutive quarter of organic revenue growth1,2\nSecond consecutive quarter of organic revenue growth1,2 across all three segments",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f04b8fb-dd6c-4930-902f-73faf686810c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.79,
        "x": 0.16,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.\n3. National Consumer Panel from IRI.\n4. IRI Panel Omnichannel. As of 4Q22.\n5. In January 2023, we acquired AcuFocus, Inc.\n6. In July 2022, we entered into certain strategic agreements with Sanoculis Ltd. (\"Sanoculis\"), including an exclusive European distribution agreement for Sanoculis Minimally Invasive Micro Sclerostomy.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e110ff5b-cc70-4050-badf-fc3c86772708",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.026,
        "w": 0.402,
        "x": 0.045,
        "y": 0.045
      },
      "kind": "title",
      "text": "4Q22 & FY22 Accomplishments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b3d3383-4eea-4df3-8990-4dcb6983c973",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "28eb7a70-62a2-4f54-922f-be4d1c9a038d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights Bausch + Lomb's accomplishments and latest guidance targets, emphasizing the need for the company's solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}